Teligent is a specialty generic pharmaceutical company (NASDAQ: TLGT). Our mission is to be a leading player in the specialty generic prescription drug market.
We have 16 Abbreviated New Drug Applications (ANDAs) on file at the FDA, representing a total addressable market of approximately $1.4 billion (IQVIA, April 2019).
We sell a portfolio of prescription topical medicines and a growing number of hospital-based sterile injectable products, including cephalosporins.
"We are forging the path to profitable growth and will continue to make the tough decisions needed to grow this business responsibly."
Teligent, Inc. to Hold Conference Call for Fourth Quarter and 2019 Full Year Financial Results on Wednesday April 8, 2020
BUENA, N.J. , April 03, 2020 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey -based specialty generic ph...Learn More
Teligent, Inc. Announces Transition in Leadership
BUENA, N.J. , Feb. 05, 2020 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT) (“Teligent” or the “Company”), a New Jerse...Learn More
Teligent, Inc. Announces FDA Request for Further Data on Complex Drug
BUENA, N.J. , Dec. 23, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey -based specialty generic pha...Learn More